Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
9Qe6BKa0Pp2kRDwf
Listen
